Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction

Safina Ali, John R. Ussher, Laurie L. Baggio, M. Golam Kabir, Maureen J. Charron, Olga Ilkayeva, Christopher B. Newgard, Daniel J. Drucker

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: Glucagon is a hormone with metabolic actions that maintains normoglycemia during the fasting state. Strategies enabling either inhibition or activation of glucagon receptor (Gcgr) signaling are being explored for the treatment of diabetes or obesity. However, the cardiovascular consequences of manipulating glucagon action are poorly understood. Methods: We assessed infarct size and the following outcomes following left anterior descending (LAD) coronary artery ligation; cardiac gene and protein expression, acylcarnitine profiles, and cardiomyocyte survival in normoglycemic non-obese wildtype mice, and in newly generated mice with selective inactivation of the cardiomyocyte Gcgr. Complementary experiments analyzed Gcgr signaling and cell survival in cardiomyocyte cultures and cell lines, in the presence or absence of exogenous glucagon. Results: Exogenous glucagon administration directly impaired recovery of ventricular pressure in ischemic mouse hearts exvivo, and increased mortality from myocardial infarction after LAD coronary artery ligation in mice in a p38 MAPK-dependent manner. In contrast, cardiomyocyte-specific reduction of glucagon action in adult GcgrCM-/- mice significantly improved survival, and reduced hypertrophy and infarct size following myocardial infarction. Metabolic profiling of hearts from GcgrCM-/- mice revealed a marked reduction in long chain acylcarnitines in both aerobic and ischemic hearts, and following high fat feeding, consistent with an essential role for Gcgr signaling in the control of cardiac fatty acid utilization. Conclusions: Activation or reduction of cardiac Gcgr signaling in the ischemic heart produces substantial cardiac phenotypes, findings with implications for therapeutic strategies designed to augment or inhibit Gcgr signaling for the treatment of metabolic disorders.

Original languageEnglish (US)
Pages (from-to)132-143
Number of pages12
JournalMolecular Metabolism
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Glucagon Receptors
Cardiac Myocytes
Glucagon
Myocardial Infarction
Ligation
Coronary Vessels
p38 Mitogen-Activated Protein Kinases
Ventricular Pressure
Hypertrophy
Fasting
Cell Survival
Fatty Acids
Obesity
Fats
Hormones
Phenotype
Gene Expression
Cell Line
Mortality

Keywords

  • Cardiomyocytes
  • Diabetes
  • Fatty acid metabolism
  • Glucagon
  • Glucagon receptor
  • Heart
  • Myocardial infarction

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. / Ali, Safina; Ussher, John R.; Baggio, Laurie L.; Kabir, M. Golam; Charron, Maureen J.; Ilkayeva, Olga; Newgard, Christopher B.; Drucker, Daniel J.

In: Molecular Metabolism, Vol. 4, No. 2, 01.02.2015, p. 132-143.

Research output: Contribution to journalArticle

Ali, Safina ; Ussher, John R. ; Baggio, Laurie L. ; Kabir, M. Golam ; Charron, Maureen J. ; Ilkayeva, Olga ; Newgard, Christopher B. ; Drucker, Daniel J. / Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. In: Molecular Metabolism. 2015 ; Vol. 4, No. 2. pp. 132-143.
@article{bd25a99ffe6b43eca48b45d6ec85e7a3,
title = "Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction",
abstract = "Objective: Glucagon is a hormone with metabolic actions that maintains normoglycemia during the fasting state. Strategies enabling either inhibition or activation of glucagon receptor (Gcgr) signaling are being explored for the treatment of diabetes or obesity. However, the cardiovascular consequences of manipulating glucagon action are poorly understood. Methods: We assessed infarct size and the following outcomes following left anterior descending (LAD) coronary artery ligation; cardiac gene and protein expression, acylcarnitine profiles, and cardiomyocyte survival in normoglycemic non-obese wildtype mice, and in newly generated mice with selective inactivation of the cardiomyocyte Gcgr. Complementary experiments analyzed Gcgr signaling and cell survival in cardiomyocyte cultures and cell lines, in the presence or absence of exogenous glucagon. Results: Exogenous glucagon administration directly impaired recovery of ventricular pressure in ischemic mouse hearts exvivo, and increased mortality from myocardial infarction after LAD coronary artery ligation in mice in a p38 MAPK-dependent manner. In contrast, cardiomyocyte-specific reduction of glucagon action in adult GcgrCM-/- mice significantly improved survival, and reduced hypertrophy and infarct size following myocardial infarction. Metabolic profiling of hearts from GcgrCM-/- mice revealed a marked reduction in long chain acylcarnitines in both aerobic and ischemic hearts, and following high fat feeding, consistent with an essential role for Gcgr signaling in the control of cardiac fatty acid utilization. Conclusions: Activation or reduction of cardiac Gcgr signaling in the ischemic heart produces substantial cardiac phenotypes, findings with implications for therapeutic strategies designed to augment or inhibit Gcgr signaling for the treatment of metabolic disorders.",
keywords = "Cardiomyocytes, Diabetes, Fatty acid metabolism, Glucagon, Glucagon receptor, Heart, Myocardial infarction",
author = "Safina Ali and Ussher, {John R.} and Baggio, {Laurie L.} and Kabir, {M. Golam} and Charron, {Maureen J.} and Olga Ilkayeva and Newgard, {Christopher B.} and Drucker, {Daniel J.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.molmet.2014.11.005",
language = "English (US)",
volume = "4",
pages = "132--143",
journal = "Molecular Metabolism",
issn = "2212-8778",
publisher = "Elsevier GmbH",
number = "2",

}

TY - JOUR

T1 - Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction

AU - Ali, Safina

AU - Ussher, John R.

AU - Baggio, Laurie L.

AU - Kabir, M. Golam

AU - Charron, Maureen J.

AU - Ilkayeva, Olga

AU - Newgard, Christopher B.

AU - Drucker, Daniel J.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective: Glucagon is a hormone with metabolic actions that maintains normoglycemia during the fasting state. Strategies enabling either inhibition or activation of glucagon receptor (Gcgr) signaling are being explored for the treatment of diabetes or obesity. However, the cardiovascular consequences of manipulating glucagon action are poorly understood. Methods: We assessed infarct size and the following outcomes following left anterior descending (LAD) coronary artery ligation; cardiac gene and protein expression, acylcarnitine profiles, and cardiomyocyte survival in normoglycemic non-obese wildtype mice, and in newly generated mice with selective inactivation of the cardiomyocyte Gcgr. Complementary experiments analyzed Gcgr signaling and cell survival in cardiomyocyte cultures and cell lines, in the presence or absence of exogenous glucagon. Results: Exogenous glucagon administration directly impaired recovery of ventricular pressure in ischemic mouse hearts exvivo, and increased mortality from myocardial infarction after LAD coronary artery ligation in mice in a p38 MAPK-dependent manner. In contrast, cardiomyocyte-specific reduction of glucagon action in adult GcgrCM-/- mice significantly improved survival, and reduced hypertrophy and infarct size following myocardial infarction. Metabolic profiling of hearts from GcgrCM-/- mice revealed a marked reduction in long chain acylcarnitines in both aerobic and ischemic hearts, and following high fat feeding, consistent with an essential role for Gcgr signaling in the control of cardiac fatty acid utilization. Conclusions: Activation or reduction of cardiac Gcgr signaling in the ischemic heart produces substantial cardiac phenotypes, findings with implications for therapeutic strategies designed to augment or inhibit Gcgr signaling for the treatment of metabolic disorders.

AB - Objective: Glucagon is a hormone with metabolic actions that maintains normoglycemia during the fasting state. Strategies enabling either inhibition or activation of glucagon receptor (Gcgr) signaling are being explored for the treatment of diabetes or obesity. However, the cardiovascular consequences of manipulating glucagon action are poorly understood. Methods: We assessed infarct size and the following outcomes following left anterior descending (LAD) coronary artery ligation; cardiac gene and protein expression, acylcarnitine profiles, and cardiomyocyte survival in normoglycemic non-obese wildtype mice, and in newly generated mice with selective inactivation of the cardiomyocyte Gcgr. Complementary experiments analyzed Gcgr signaling and cell survival in cardiomyocyte cultures and cell lines, in the presence or absence of exogenous glucagon. Results: Exogenous glucagon administration directly impaired recovery of ventricular pressure in ischemic mouse hearts exvivo, and increased mortality from myocardial infarction after LAD coronary artery ligation in mice in a p38 MAPK-dependent manner. In contrast, cardiomyocyte-specific reduction of glucagon action in adult GcgrCM-/- mice significantly improved survival, and reduced hypertrophy and infarct size following myocardial infarction. Metabolic profiling of hearts from GcgrCM-/- mice revealed a marked reduction in long chain acylcarnitines in both aerobic and ischemic hearts, and following high fat feeding, consistent with an essential role for Gcgr signaling in the control of cardiac fatty acid utilization. Conclusions: Activation or reduction of cardiac Gcgr signaling in the ischemic heart produces substantial cardiac phenotypes, findings with implications for therapeutic strategies designed to augment or inhibit Gcgr signaling for the treatment of metabolic disorders.

KW - Cardiomyocytes

KW - Diabetes

KW - Fatty acid metabolism

KW - Glucagon

KW - Glucagon receptor

KW - Heart

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84921892213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921892213&partnerID=8YFLogxK

U2 - 10.1016/j.molmet.2014.11.005

DO - 10.1016/j.molmet.2014.11.005

M3 - Article

VL - 4

SP - 132

EP - 143

JO - Molecular Metabolism

JF - Molecular Metabolism

SN - 2212-8778

IS - 2

ER -